{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:59:28Z","timestamp":1792004368244,"version":"4.4.0"},"reference-count":51,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2024,11,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study reports the activity of cefiderocol against Enterobacterales,\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      , and\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      spp. isolates collected from the United States and Europe, including Israel and Turkey, from 2020 to 2021. Among Enterobacterales, 2.8% were carbapenem nonsusceptible (CNSE); cefiderocol inhibited 96.6%\/85.1% [Clinical Laboratory Standards Institute (CLSI)\/European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints] of these isolates. Imipenem-relebactam, meropenem-vaborbactam, and ceftazidime-avibactam displayed susceptibilities lower than cefiderocol against CNSE isolates (67.4\u201384.6% susceptible, CLSI). Cefiderocol was the only agent active against CNSE isolates carrying metallo-\u03b2-lactamase (MBL) carbapenemase or multiple carbapenemase genes (84.6%\u201392.3% susceptible, CLSI). Approximately 18% of carbapenem-susceptible\n                      <jats:italic>Escherichia coli<\/jats:italic>\n                      ,\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      , and\n                      <jats:italic>Proteus mirabilis<\/jats:italic>\n                      carried extended-spectrum-\u03b2-lactamases and\/or plasmid-borne AmpC-encoding genes; cefiderocol inhibited 99.8%\u2013100.0% (CLSI) of these genotypic groups. Multi-drug resistance (MDR) phenotypes were observed in 16.9% and 52.5% of\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      and\n                      <jats:italic>A. baumannii-calcoaceticus<\/jats:italic>\n                      isolates, respectively. Carbapenemase genes were rare (4.9%) among cephalosporin and\/or carbapenem nonsusceptible\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      , compared to 87.6% carriage in\n                      <jats:italic>A. baumannii-calcoaceticus<\/jats:italic>\n                      , respectively. Against the MDR and carbapenemase-carrying\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      and\n                      <jats:italic>A. baumannii-calcoaceticus<\/jats:italic>\n                      subsets, cefiderocol was active against 98.6%\/98.7% and 97.1%\/97.4% (CLSI), respectively. Only 69 isolates (0.3%) across all species groups were identified as cefiderocol nonsusceptible per CLSI criteria (&gt;4 mg\/L). Cefiderocol was the most active agent\n                      <jats:italic>in vitro<\/jats:italic>\n                      against Enterobacterales,\n                      <jats:italic>P. aeruginosa,<\/jats:italic>\n                      and\n                      <jats:italic>Acinetobacter<\/jats:italic>\n                      spp., with uniform activity against all phenotypic- and genotypic-resistant subsets. Coupled with the low incidence of nonsusceptibility observed across species groups, these results demonstrate cefiderocol as an important option for treating infections caused by pathogens with diverse mechanisms of resistance in US and European hospitals.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        The worldwide spread of multi-drug-resistant\n                        <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                        and carbapenem-resistant Enterobacterales and\n                        <jats:italic>Acinetobacter<\/jats:italic>\n                        spp. poses a serious challenge in healthcare settings as infections caused by these organisms are commonly refractory to many frontline therapeutic agents. Multiple global health organizations highlighted these pathogens as critical priorities for new antibiotic development, thus necessitating continued surveillance of the activities of currently available antimicrobial agents and circulating mechanisms of resistance. To meet this need, this study phenotypically and genotypically characterized priority Gram-negative pathogens collected from patients in US and European hospitals to examine the activity of cefiderocol and other currently available treatment options, including carbapenems and \u03b2-lactam-\u03b2-lactamase inhibitor combinations. The results presented here provide a detailed perspective to healthcare practitioners of cefiderocol\u2019s broad applicability, manifested in high activity and low nonsusceptibility rates, across phenotypic and genotypic organism groups relative to other agents and further support its use against the most intransigent infections.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.01474-24","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T09:01:42Z","timestamp":1728550902000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["<i>In vitro<\/i>\n                    activity assessment of cefiderocol against Enterobacterales,\n                    <i>Pseudomonas aeruginosa,<\/i>\n                    and\n                    <i>Acinetobacter<\/i>\n                    spp., including \u03b2-lactam nonsusceptible molecularly characterized isolates, collected from 2020 to 2021 in the United States and European hospitals"],"prefix":"10.1128","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-1543","authenticated-orcid":true,"given":"John H.","family":"Kimbrough","sequence":"first","affiliation":[{"name":"JMI Laboratories\/Element Iowa City, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2841-6855","authenticated-orcid":true,"given":"Joshua M.","family":"Maher","sequence":"additional","affiliation":[{"name":"JMI Laboratories\/Element Iowa City, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":true,"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories\/Element Iowa City, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":true,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories\/Element Iowa City, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":false,"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories\/Element Iowa City, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","unstructured":"CDC. 2019. Antibiotic resistance threats in the United States 2019. Available from: https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf?CDC_AAref_Val=https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Retrieved Aug 2024."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy378"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1478"},{"key":"e_1_3_4_5_2","unstructured":"WHO. 2017. Prioritization of pathogens to guide discovery research and development of new antibiotics for drug-resistant bacterial infections including tuberculosis. World Health Organization Geneva Switzerland. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/311820"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac089"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01454-17"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03098-15"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky317"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.005"},{"key":"e_1_3_4_11_2","volume-title":"Fetcroja [package insert]","author":"Shionogi","year":"2020","unstructured":"Shionogi. 2020. Fetcroja [package insert]. European Medicines Agency, Amsterdam."},{"key":"e_1_3_4_12_2","volume-title":"M100. Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. M100. Performance standards for antimicrobial susceptibility testing. 33rd Edition. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"33"},{"key":"e_1_3_4_13_2","unstructured":"USFDA. 2023. Antibacterial susceptibility test interpretive criteria. Washington DC. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria"},{"key":"e_1_3_4_14_2","unstructured":"EUCAST. 2023. Clinical breakpoints - breakpoints and guidance. V\u00e4xj\u00f6 Sweden. Available from: https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac098"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad032"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad046"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa011"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz125"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101373"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.6.2000085"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac078"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac082"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab888"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02011-21"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa355"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","unstructured":"CDC. 2018. Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms \u2014 United States 2006\u20132017. CDC Atlanta GA. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/67\/wr\/mm6713e1.htm","DOI":"10.15585\/mmwr.mm6713e1"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00496-22"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2022.0279"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2048972"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1909"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab311"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad107"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10050720"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-18"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01897-13"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.114999"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01990-21"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00877-21"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01192-23"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2909.230390"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00617-23"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02171-20"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11121686"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab115"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2020.1856921"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2660"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa150"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac391"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy346"},{"key":"e_1_3_4_52_2","volume-title":"M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz004"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01474-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.01474-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:42:17Z","timestamp":1730799737000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.01474-24"}},"subtitle":[],"editor":[{"given":"Pablo","family":"Power","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,5]]}},"alternative-id":["10.1128\/spectrum.01474-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.01474-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"2024-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01474-24"}}